Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 19, Number 8—August 2013


Macrolide Resistance of Mycoplasma pneumoniae, South Korea, 2000–2011

Ki Bae Hong, Eun Hwa ChoiComments to Author , Hoan Jong Lee, Seong Yeon Lee, Eun Young Cho, Jae Hong Choi, Hyun Mi Kang, Jina Lee, Young Min Ahn, Yeon-Ho Kang, and Joon-Ho Lee
Author affiliations: Seoul National University Hospital, Seoul, South Korea (K.B. Hong, E.H. Choi, H.J. Lee, S.Y. Lee, E.Y. Cho, J.H. Choi, H.M. Kang); Seoul National University College of Medicine, Seoul (E.H. Choi, H.J. Lee); Seoul National University Bundang Hospital, Seongnam, South Korea (J. Lee); Seoul Eulji Hospital, Seoul (Y.M. Ahn); Korea Centers for Disease Control and Prevention, Seoul (Y.-H. Kang); Kangwon National University Hospital, Chuncheon, South Korea (J.-H. Lee)

Main Article

Table 2

MICs of tetracyclines and fluoroquinolones for Mycoplasma pneumoniae strains in a study of macrolide resistance, South Korea, 2000–2011*

Antimicrobial drug Strains with 23S rRNA mutation, n = 69
Strains without 23S rRNA mutation, n = 54
Range MIC50 MIC90 Range MIC50 MIC90
Tetracycline 0.016 to 0.5 0.06 0.25 0.016 to 0.5 0.06 0.25
0.002 to 0.125

0.004 to 0.125
Levofloxacin 0.016 to 0.5 0.25 0.25 0.016 to 0.5 0.25 0.5
Ciprofloxacin 0.125 to 1.0 0.5 1.0 0.06 to 1.0 0.5 1.0
Moxifloxacin 0.008 to 0.06 0.016 0.06 0.004 to 0.06 0.016 0.06

*MIC50 and MIC90 are minimum inhibitory concentrations at which 50% and 90% of the isolates, respectively, were inhibited by the drug.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO